Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Zelboraf (Vemurafenib),Zelb2020US,2020,USA,MDV,350,62,40,60,27.5,65,85,0,15,30,40,15,55,30,10,5,20,35,45,12,5,3,7,4,0,10,25,,,Dacarbazine,Interferon alfa-2b,0,0,0,30,40,50,15,50,35,60,2
Zelboraf (Vemurafenib),Zelb2021EU,2021,Germany,Claim Database,420,68,35,65,26.8,70,78,0,12,28,45,15,60,25,10,5,18,32,50,15,8,4,9,5,0,12,28,,,Dacarbazine,High-dose Interferon alfa-2b,0,0,0,35,45,55,20,45,35,55,1.5
Zelboraf (Vemurafenib),Zelb2022JP,2022,Japan,MDV,280,70,45,55,25.5,55,90,0,18,32,35,15,70,20,5,5,25,40,35,10,4,2,6,3,0,8,22,,,Dacarbazine,Nivolumab,0,0,0,25,35,45,25,40,35,70,2.5
Zelboraf (Vemurafenib),Zelb2023CA,2023,Canada,Claim Database,380,65,38,62,28.0,60,82,0,14,29,42,15,58,28,9,5,19,33,48,13,6,3,8,4,0,11,26,,,Dacarbazine,Ipilimumab,0,0,0,32,42,52,18,48,34,62,1.8
